Singapore's Health Sciences Authority (HSA) and the Department of Health (DoH), Hong Kong Special Administrative Region (HKSAR), have signed a Memorandum of Understanding (MoU) for cooperation in healthcare regulatory matters pertaining to health products. This MoU marks an important milestone in strengthening ties between the two regulatory authorities.
The MoU encompasses technical cooperation and mutual exchange of information, best practices and expertise pertaining to healthcare regulatory matters across a broad spectrum of health products, including pharmaceuticals, medical devices, advanced therapy products and traditional medicines.
The agreement also facilitates the sharing of regulatory information and enforcement approaches towards tobacco products and vaping devices. To support these objectives, the MoU enables exchange of regulatory experts and staff, participation in meetings and scientific conferences, as well as collaboration in training courses and joint projects.
This collaboration underscores Singapore and Hong Kong’s shared commitment to ensuring the safety, quality and efficacy of health products and to advancing regulatory excellence in our jurisdictions.
“This partnership represents a significant step forward in regulatory cooperation between Singapore and Hong Kong,” said HSA Chief Executive Officer, Adjunct Professor (Dr) Raymond Chua. “By combining our expertise and sharing best practices, we can better tackle the emerging challenges in healthcare regulation, harness opportunities and strengthen public health protection in both jurisdictions."
